Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

NCTID NCT05144386 (View at clinicaltrials.gov)
Description
Indication HIV-1 Infection, subgroup B
Compound Name EBT-101 (AAV9-SaCas9-GagD-LTR1)
Sponsor Excision BioTherapeutics
Funder Type Industry
Status
Active not recruiting
Enrollment Count 6

Therapy Information

Target Gene/Variant HIV genes
Therapy Type Gene editing
Therapy Route In-vivo
Mechanism of Action Gene excision
Route of Administration Intravenous
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV9
Editor Type Cas9
Dose 1 0.9 x 10^12 vg/kg
Dose 2 3.0 x 10^12 vg/kg
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Phase1
Submit Date 2021-11-22
Completion Date 2025-05
Last Update 2024-07-29

Participation Criteria

Eligible Age 18 Years - 70 Years
Standard Ages Adult, Older adult
Eligible Sex MALE

Locations

No.of Trial Sites 3
Locations United States

Regulatory Information

Has US IND True
Recent Updates Safe, but does not provide long-term viral suppression

Resources/Links

Patents
  • US20190367924A1
  • US20200392487A1
  • US20240139294A1
Grant
  • R01 MH115860
  • R01 MH110360
  • R01 HL114152
  • R56 AI143647
  • R56 AI150772
  • R01 DA042706
  • CLIN2-13310
  • R01 NS087971
News and Press Releases
Preclinical Publications